Stella PharmaSTELLA PHARMA CORPORATION4888東証グロース医薬品FY ending Mar 2026, non-consolidated, J-GAAP
It lost about ¥232 for every ¥100 of sales at the operating level. Revenue changed -66.4% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -16.3% | —× | — |
| 2023 | — | —× | -17.2% | —× | — |
| 2024 | — | —× | -18.7% | —× | — |
| 2025 | — | —× | -3.0% | —× | — |
| 2026 | — | —× | -15.8% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 100 | 229 | 269 | 961 | 323 |
| Cost of revenue | 15 | 22 | 52 | 115 | 44 |
| Gross profit | 85 | 207 | 217 | 846 | 279 |
| SG&A | 827 | 1,014 | 978 | 936 | 1,028 |
| Operating income | -742 | -807 | -760 | -90 | -749 |
| Pretax income | -764 | -776 | -761 | -138 | -778 |
| Income tax | 4 | 3 | 3 | 3 | 3 |
| Net income attributable to owners | -768 | -779 | -764 | -141 | -781 |
| Operating margin | -741.2% | -352.2% | -282.1% | -9.4% | -231.6% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.24B | ¥2.67B | ¥2.01B | ¥3.16B | ¥2.78B |
| Total assets | ¥4.72B | ¥4.33B | ¥3.82B | ¥5.42B | ¥4.49B |
| Net assets | ¥3.08B | ¥2.75B | ¥2.38B | ¥3.21B | ¥2.43B |
| Share capital | ¥3.81B | ¥3.3B | ¥2.94B | ¥2.86B | ¥2.86B |
| Property, plant and equipment | ¥92M | ¥102.9M | ¥81.5M | ¥66.5M | ¥47.1M |
| Intangible assets excluding goodwill | ¥68.4M | ¥61.7M | ¥52.5M | ¥49.3M | ¥42.7M |
| Investment securities | ¥304.5M | ¥302.7M | — | — | — |
| Current assets | ¥4.18B | ¥3.79B | ¥3.63B | ¥5.24B | ¥4.35B |
| Current liabilities | ¥308.1M | ¥421.6M | ¥455.6M | ¥390.4M | ¥260M |
| Long-term borrowings | ¥1.09B | ¥933.3M | ¥773.3M | ¥608.1M | ¥588.5M |
| Total liabilities | ¥1.64B | ¥1.58B | ¥1.44B | ¥2.21B | ¥2.06B |
| Equity attributable to owners of parent | ¥3.08B | ¥2.74B | ¥2.37B | ¥3.21B | ¥2.43B |
| Retained earnings | -¥2.64B | -¥778.8M | -¥763.7M | -¥140.8M | -¥780.9M |
| Treasury stock | — | -¥30K | -¥30K | -¥56K | -¥56K |
EDINET (FSA Japan)
有価証券報告書－第19期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第18期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第17期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第16期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第15期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第14期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 39 / Derived from other figures: 2
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.